financetom
Business
financetom
/
Business
/
Cass Information Systems misses Q2 revenue estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cass Information Systems misses Q2 revenue estimates
Jul 17, 2025 5:48 AM

Overview

* Cass Information Systems ( CASS ) Q2 revenue missed analyst expectations, per LSEG data

* Net income for Q2 rises to $8.9 mln, driven by improved net interest margin

* Co closed sale of TEM business, gaining $3.6 mln, repurchased 140,269 shares

Outlook

* Cass, which provides payment and information processing services and runs a bank expects freight rate momentum to support fee income.

* Company anticipates neutral profitability post-TEM business sale.

* Cass sees increased interest income from redeployment of sale proceeds.

Result Drivers

* NET INTEREST INCOME - Driven by growth in interest-earning assets and improved net interest margin, per CEO Martin Resch

* TEM BUSINESS SALE - Sale resulted in a gain of $3.6 million

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $44.40 $51 mln

Revenue mln (1

Analyst)

Q2 Net $8.86

Income mln

Q2 Net $19.48

Interest mln

Income

Q2 $38.12

Operatin mln

g

Expenses

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the business support services peer group is "buy"

* Wall Street's median 12-month price target for Cass Information Systems Inc ( CASS ) is $50.00, about 10.8% above its July 16 closing price of $44.61

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EXPLAINER-Everything you need to know about the 2025 Super Bowl 
EXPLAINER-Everything you need to know about the 2025 Super Bowl 
Dec 16, 2024
(Changes headline. No changes to text) Dec 16 (Reuters) - The NFL season is in its home stretch, and with the playoff picture becoming more clear fans are sizing up their team's prospects for making it to the Super Bowl, arguably the biggest single event in U.S. sports with a huge global audience. Here's everything you need to know about...
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia
Dec 16, 2024
08:52 AM EST, 12/16/2024 (MT Newswires) -- Reviva Pharmaceuticals ( RVPH ) said Monday that preliminary topline data from a phase 3 study of brilaroxazine in patients with schizophrenia was positive as it demonstrated robust broad-spectrum efficacy that was sustained for more than one year. The biopharmaceutical company also said brilaroxazine was generally well tolerated with no single side effect...
Carlyle agrees to sell Italy's Forgital to Stonepeak
Carlyle agrees to sell Italy's Forgital to Stonepeak
Dec 16, 2024
MILAN, Dec 16 (Reuters) - Private equity firm Carlyle has agreed to sell Italian firm Forgital, which manufactures forged components mainly for the aerospace sector, to U.S. alternative investment firm Stonepeak, the two companies said on Monday. The deal gives the Italian company an enterprise value of around 2 billion euros ($2.10 billion), a source close to the matter told...
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall
Dec 16, 2024
08:53 AM EST, 12/16/2024 (MT Newswires) -- PepGen ( PEPG ) said Monday it has received a Food and Drug Administration clinical hold notice for its investigational new drug application to initiate a phase 2 trial of PGN-EDO51, a potential treatment for Duchenne muscular dystrophy. The regulator will send an official clinical hold letter within 30 days, the company said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved